Articles

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
Department of Molecular Pharmacology & Experimental Therapeutics, Rochester, NY
Division of Oncology Research and Mayo Clinic, Rochester, NY
Division of Oncology Research and Mayo Clinic, Rochester, NY
Division of Oncology Research and Mayo Clinic, Rochester, NY
Division of Oncology Research and Mayo Clinic, Rochester, NY
Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
Division of Hematological Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
Division of Hematological Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
Department of Molecular Pharmacology & Experimental Therapeutics, Rochester, NY;Division of Oncology Research and Mayo Clinic, Rochester, NY
Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
Vol. 99 No. 4 (2014): April, 2014 https://doi.org/10.3324/haematol.2013.093187